Nesiritide: The Recombinant BNP for Heart Failure

Natriuretic Peptides

7,141 patients

The ASCEND-HF trial enrolled 7,141 patients across 398 centers and found no mortality benefit for nesiritide over placebo.

O'Connor et al., NEJM, 2011

O'Connor et al., NEJM, 2011

View as image

Nesiritide was the first recombinant peptide drug designed to replicate what the natriuretic peptide system does naturally: lower cardiac filling pressures, promote sodium excretion, and relieve the fluid overload that defines acute heart failure. Sold under the brand name Natrecor by Scios (later Janssen Pharmaceuticals), it is a 32-amino-acid peptide structurally identical to endogenous human B-type natriuretic peptide (BNP). The FDA approved nesiritide in August 2001 for acute decompensated heart failure (ADHF). By 2004, annual sales reached $400 million. By 2018, the manufacturer discontinued production. That arc, from blockbuster to withdrawal, tracks one of the most instructive cautionary tales in peptide drug development. The peptide worked exactly as pharmacology predicted. The clinical outcomes did not follow. Understanding why natriuretic peptides failed as a drug while succeeding as a biomarker remains relevant to anyone studying peptide therapeutics today.

How Nesiritide Works: Mechanism of Action

Nesiritide binds to the natriuretic peptide receptor A (NPR-A) on vascular smooth muscle cells, endothelial cells, kidney tubular cells, and adrenal glands. This receptor activation increases intracellular cyclic GMP (cGMP), which triggers three simultaneous effects: vasodilation (reducing preload and afterload), natriuresis (promoting sodium and water excretion), and suppression of the renin-angiotensin-aldosterone system.

The hemodynamic profile distinguishes nesiritide from other vasodilators used in heart failure. It produces balanced venous and arterial dilation, reduces pulmonary capillary wedge pressure (PCWP) and right atrial pressure, and increases cardiac output without directly increasing heart rate.^[1] Unlike dobutamine and milrinone, nesiritide has no direct inotropic effect and does not increase myocardial oxygen demand.

The peptide has a two-compartment pharmacokinetic profile: a distribution half-life of approximately 2 minutes and a terminal elimination half-life of 18 minutes. Three clearance pathways operate in parallel: binding to the NPR-C clearance receptor (internalization and lysosomal degradation), hydrolysis by neprilysin (neutral endopeptidase 24.11) on vascular endothelial surfaces, and glomerular filtration by the kidneys. Clearance averages 0.55 L/h/kg and is proportional to body weight, which is why dosing is weight-based: a 2 mcg/kg bolus followed by 0.01 mcg/kg/min continuous infusion.

This mechanism is pharmacologically identical to what happens when the heart releases endogenous BNP in response to ventricular stretch. The difference is concentration. In ADHF patients, endogenous BNP levels are already elevated (often 500-2,000 pg/mL), reflecting the body's attempt to compensate for volume overload. Exogenous nesiritide pushes natriuretic peptide signaling beyond what the body can achieve alone, amplifying the compensatory response. The question was whether that amplification translates to better outcomes.

The Trials That Built Nesiritide

Colucci 2000: The First Pivotal Trial

The first major trial, published in the New England Journal of Medicine in July 2000, enrolled 432 patients hospitalized with decompensated CHF across 55 centers.^[1] The study had two parts. In the efficacy trial, 127 patients with a PCWP of 18 mmHg or higher received nesiritide (0.015 or 0.030 mcg/kg/min) or placebo for 6 hours. At 6 hours, nesiritide at the lower dose decreased PCWP by 6.0 mmHg, and the higher dose by 9.6 mmHg, compared with a 2.0 mmHg increase with placebo (P<0.001).

Clinical improvements were equally striking. Global clinical status improved in 60% and 67% of nesiritide patients versus 14% on placebo. Dyspnea decreased in 57% and 53% versus 12%. Fatigue improved in 32% and 38% versus 5%. All differences were statistically significant. The comparative trial (305 patients) showed these improvements were sustained for up to 7 days and were similar to standard IV heart failure therapy. The primary side effect was dose-related hypotension, usually asymptomatic.

VMAC 2002: The Approval Trial

The Vasodilation in the Management of Acute CHF (VMAC) trial, published in JAMA in 2002, directly compared nesiritide to nitroglycerin in 489 patients. Nesiritide reduced PCWP by 5.8 mmHg at 3 hours, compared with 3.8 mmHg for nitroglycerin (P=0.03). At 24 hours, nesiritide maintained a 2.4 mmHg advantage. Patient-reported dyspnea improved more with nesiritide than placebo at 3 hours, though the difference versus nitroglycerin at 3 hours was not statistically significant. The FDA approved nesiritide based largely on these hemodynamic improvements.

Post-Approval Adoption

Between 2001 and 2005, nesiritide use grew rapidly. Scios marketed it as a first-line treatment for ADHF, and some centers began using it for outpatient infusions, a use not supported by the FDA label. By 2004, over 600,000 patients had received the drug, and annual sales exceeded $400 million.

The Safety Controversy

Sackner-Bernstein Meta-Analyses (2005)

The trajectory changed with two meta-analyses published within weeks of each other in 2005. Jonathan Sackner-Bernstein and colleagues pooled data from the available randomized trials and published alarming findings.

The first, in Circulation (March 2005), analyzed renal outcomes across 5 RCTs with 1,269 patients. Nesiritide at FDA-approved doses increased the risk of worsening renal function (defined as serum creatinine increase >0.5 mg/dL) compared with non-inotrope control therapy. The finding was statistically significant and raised immediate concerns, given that renal impairment in heart failure patients is associated with higher mortality.

The second meta-analysis, in JAMA (April 2005), examined 30-day mortality across 3 RCTs with 862 patients. Death occurred in 7.2% (35 of 485) of nesiritide patients versus 4.0% (15 of 377) of controls, yielding a risk ratio of 1.74 (95% CI: 0.97-3.12, P=0.059). The trend did not reach conventional statistical significance, but the point estimate, a 74% increase in mortality risk, was concerning enough to trigger an FDA review.

Regulatory and Clinical Fallout

The FDA took several steps. In April 2005, it required Scios to add enhanced warnings about the risk of death and renal impairment to the Natrecor label. A warning letter was sent to physicians. The FDA also convened an advisory panel and urged the manufacturer to conduct a large definitive trial. Nesiritide prescribing dropped sharply. From its peak usage, prescriptions declined by more than 50% within a year of the meta-analyses.

ASCEND-HF: The Definitive Trial

The Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure (ASCEND-HF) was designed to resolve the safety question. Published in the New England Journal of Medicine in July 2011, it enrolled 7,141 patients at 398 centers worldwide between May 2007 and August 2010. Patients hospitalized with ADHF received either nesiritide or placebo for 24 to 168 hours, in addition to standard care.

Primary Endpoints

Two coprimary endpoints were tested. For dyspnea at 6 and 24 hours, nesiritide produced modestly higher rates of "markedly or moderately improved" self-assessment: 44.5% versus 42.1% at 6 hours (P=0.03) and 68.2% versus 66.1% at 24 hours (P=0.007). The prespecified significance threshold was P<0.005, so these differences did not meet the trial's own bar.

For the composite of rehospitalization for heart failure or death within 30 days, rates were 9.4% in the nesiritide group versus 10.1% in the placebo group (absolute difference: -0.7 percentage points, 95% CI: -2.1 to 0.7, P=0.31). There was no statistically significant benefit.

Safety Findings

ASCEND-HF did at least settle the safety debate. Worsening renal function occurred at similar rates in both groups (31.4% nesiritide vs 31.1% placebo). The 30-day mortality was 3.6% in both arms. Nesiritide did not worsen kidney function or increase death. But it also did not reduce them. Hypotension was more common with nesiritide (26.6% vs 15.3%).

The conclusion: nesiritide was not harmful, but it was also not beneficial beyond minor symptomatic relief that did not reach the trial's own significance threshold. For a drug that cost substantially more than generic alternatives like nitroglycerin and that required continuous IV infusion, this was a death sentence. There was no clinical reason to use it.

Why the Peptide Failed as a Drug

The nesiritide story raises a question relevant across peptide drug development: why did a molecule that perfectly replicates an endogenous peptide, binds to the correct receptor, and produces the expected hemodynamic changes fail to improve outcomes?

Several factors contributed:

Redundancy with the compensatory response. In ADHF, BNP levels are already elevated 10- to 100-fold above normal. The heart is already maximally stimulating the natriuretic peptide pathway. Adding exogenous BNP pushes a system that is already at or near saturation. Receptor downregulation may limit additional benefit.

Short duration relative to the disease. Heart failure decompensation reflects weeks to months of worsening hemodynamics. A 24-168 hour peptide infusion addresses the immediate hemodynamic crisis but does nothing about the underlying neurohormonal activation, cardiac remodeling, or fluid redistribution that caused the decompensation.

Hemodynamic endpoints are not clinical endpoints. The trials showed clear hemodynamic improvements: lower filling pressures, improved cardiac output. But these surrogate markers did not translate to reduced mortality, shorter hospital stays, or fewer readmissions. This disconnect between hemodynamics and outcomes has been observed with other heart failure drugs, including milrinone.

Hypotension as a limiting factor. The 26.6% rate of hypotension in ASCEND-HF limited dose optimization. Patients who might have benefited from higher doses could not tolerate them. The drug's vasodilatory effect, its primary mechanism, was also its primary adverse effect.

Recombinant BNP After Nesiritide: The rhBNP Story

While nesiritide (Natrecor) was discontinued in the U.S. in 2018, recombinant human BNP (rhBNP, marketed as Xinhuosu) has continued to be studied and used in China. Chinese trials have focused on specific clinical scenarios where rhBNP may offer clearer benefits.

A 2020 meta-analysis of 12 randomized controlled trials (1,826 patients) evaluated nesiritide specifically in patients with acute myocardial infarction complicated by heart failure.^[2] In this population, nesiritide improved left ventricular ejection fraction, reduced BNP levels, and decreased the incidence of major adverse cardiac events compared with standard therapy. This suggests the peptide may have a more defined role when heart failure is driven by acute ischemia rather than chronic decompensation.

A retrospective study of 96 STEMI patients found that adding rhBNP to standard PCI therapy improved LVEF (from 43.1% to 51.7% at discharge) and reduced NT-proBNP levels more than PCI alone.^[4]

Sequential treatment approaches have also shown promise. Pang et al. (2021) studied 300 patients with acute heart failure and found that rhBNP followed by sacubitril/valsartan produced greater improvements in cardiac structure, lower pulmonary artery pressures, and reduced inflammatory markers compared with rhBNP alone.^[5] This strategy of using the peptide to stabilize acute hemodynamics and then transitioning to an oral neprilysin inhibitor (which preserves endogenous natriuretic peptides) represents a more integrated approach.

Meng et al. (2025) demonstrated that rhBNP combined with vasoactive medications was safe and effective even in elderly patients with heart failure and concurrent hypotension, a population traditionally excluded from vasodilator therapy.^[7] And a 2026 trial of 172 patients showed rhBNP improved outcomes in ADHF patients with atrial fibrillation who had failed conventional therapy.^[6]

These Chinese studies have limitations. Most are single-center, many are retrospective, and they use rhBNP formulations that may differ from nesiritide in manufacturing and purity. None approach the scale of ASCEND-HF. But they suggest that recombinant BNP may retain a role in specific clinical niches rather than as a broad ADHF treatment.

BNP's Lasting Legacy: The Biomarker That Outlived the Drug

The paradox of the nesiritide story is that while recombinant BNP failed as a drug, BNP and its cleavage fragment NT-proBNP became among the most important biomarkers in all of medicine.

Troughton et al. (2000) demonstrated that guiding heart failure treatment by plasma NT-proBNP concentrations produced better outcomes than empirical clinical management alone.^[8] The STARS-BNP Multicenter Study (Jourdain et al., 2007) confirmed that BNP-guided therapy in chronic heart failure reduced heart failure-related death and hospital admissions compared with standard clinical management in 220 patients.^[9]

Today, BNP and NT-proBNP assays are standard components of heart failure diagnosis, prognosis, and treatment monitoring. A peptide that failed as an exogenous therapy succeeded as an endogenous signal, one that tells clinicians exactly how much hemodynamic stress the heart is under. The molecule's biology was never wrong. The therapeutic strategy was.

What Nesiritide Teaches About Peptide Drug Design

The nesiritide arc offers several lessons for the broader field of cardiovascular peptide therapeutics:

Replicating an endogenous peptide is not enough. The body's compensatory mechanisms are complex, redundant, and context-dependent. Flooding a system with more of a peptide that the body is already producing at high levels may not produce additive benefit.

Hemodynamic surrogates can mislead. PCWP reduction, increased cardiac output, and improved renal blood flow are all pharmacologically desirable. None predicted clinical outcomes in the nesiritide trials. Drug development programs that rely on hemodynamic endpoints without hard outcome data risk the same trap.

Timing and patient selection matter. The broad ADHF population in ASCEND-HF may have diluted benefit in subgroups that genuinely respond. The Chinese rhBNP data suggests that acute MI patients and those who fail conventional therapy may benefit more than the general ADHF population. Future peptide heart failure drugs will likely need more precise targeting.

Safety signals in small trials must be taken seriously. The Sackner-Bernstein meta-analyses used small datasets but raised legitimate concerns. ASCEND-HF ultimately showed nesiritide was safe, but the years of uncertainty and the $170 million cost of the trial could have been avoided with earlier, better-designed studies.

The path from ANP's discovery in the 1980s to sacubitril/valsartan (Entresto) in 2015, which works by preventing natriuretic peptide breakdown rather than adding exogenous peptide, suggests the field learned from nesiritide's failure. Instead of pushing more BNP into an already-saturated system, the newer approach preserves and amplifies the patient's own natriuretic peptide signaling. Sacubitril/valsartan reduced cardiovascular death by 20% in the PARADIGM-HF trial, something nesiritide never achieved.

The Bottom Line

Nesiritide was a pharmacologically sound recombinant peptide that produced the expected hemodynamic effects but failed to improve clinical outcomes in the largest heart failure trial ever conducted at the time. Its story illustrates why surrogate endpoints can mislead, why patient selection matters, and why endogenous peptide biology does not always translate to exogenous drug success. The molecule's lasting contribution was not as a drug but as a biomarker: BNP and NT-proBNP remain central to heart failure diagnosis and management worldwide.

Frequently Asked Questions

What is nesiritide used for?

Nesiritide (brand name Natrecor) was an intravenous drug used for acute decompensated heart failure in patients with dyspnea at rest or with minimal activity. It was FDA-approved in August 2001 and discontinued by Janssen Pharmaceuticals in February 2018 after the ASCEND-HF trial showed no significant benefit on mortality or rehospitalization compared with placebo.

Why was nesiritide discontinued?

The manufacturer discontinued nesiritide in 2018 because the 7,141-patient ASCEND-HF trial (O'Connor et al., 2011) showed it did not reduce death or rehospitalization rates compared with placebo. While it modestly improved dyspnea symptoms, the improvement did not meet the trial's own significance threshold. With no proven benefit over cheaper alternatives like nitroglycerin, clinical use dropped to near zero.

Is nesiritide the same as BNP?

Nesiritide is structurally identical to endogenous human B-type natriuretic peptide (BNP). It is a 32-amino-acid recombinant peptide produced using E. coli expression systems. The molecule binds the same NPR-A receptor and triggers the same cGMP-mediated vasodilation and natriuresis as the BNP your heart produces naturally.

What replaced nesiritide for heart failure?

No direct replacement exists for IV recombinant BNP. The field shifted toward sacubitril/valsartan (Entresto), which inhibits neprilysin to prevent breakdown of the body's own natriuretic peptides rather than adding exogenous BNP. Sacubitril/valsartan reduced cardiovascular death by 20% in the PARADIGM-HF trial, a benefit nesiritide never demonstrated.

Does nesiritide cause kidney damage?

The 2005 Sackner-Bernstein meta-analysis raised concerns about worsening renal function with nesiritide. The larger ASCEND-HF trial (7,141 patients) found no difference in renal outcomes: worsening renal function occurred in 31.4% of nesiritide patients versus 31.1% of placebo patients. The kidney damage concern was ultimately not confirmed.

Is recombinant BNP still used anywhere?

Recombinant human BNP (rhBNP, marketed as Xinhuosu) remains in clinical use in China. Chinese trials continue to study it for acute MI with heart failure, ADHF with atrial fibrillation, and as a bridge to oral heart failure medications like sacubitril/valsartan. These studies are smaller than ASCEND-HF and use locally manufactured formulations.